$Galera Therapeutics, Inc.(GRTX)$ Company plans to discuss avasopasem data with the FDA in 2022 together with the randomized Phase 2b trial could suport an NDA submission, ➡️ other upcoming catalyst including initial data from GREO-1 trial (trials in lung and pancreatic cancer) in the first half of 2022, BTIG Upgrades to Buy price target 15
精彩评论